Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Chalmers

Showing results (471-480 of 494) with videos related to

Pageof 50
Sort By:
The Lancet. Respiratory Medicine|April 27, 2026
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort studyAmelia Shoemark, Emma D Johnson, Morven Shuttleworth, et al.
Eclinicalmedicine|March 20, 2023
Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort studyHamish J C McAuley, Rachael A Evans, Charlotte E Bolton, et al.
Thorax|March 23, 2025
Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)Jennifer Pollock, Eva Polverino, Raja Dhar, et al.
The European Respiratory Journal|April 12, 2024
Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)Stefano Aliberti, Felix C Ringshausen, Raja Dhar, et al.
Ebiomedicine|December 21, 2022
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccinationFelicity Liew, Shubha Talwar, Andy Cross, et al.
The Lancet. Respiratory Medicine|August 30, 2025
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational studyOriol Sibila, Jamie Stobo, Lidia Perea, et al.
Trials|January 26, 2023
The effect of COVID rehabilitation for ongoing symptoms Post HOSPitalisation with COVID-19 (PHOSP-R): protocol for a randomised parallel group controlled trial on behalf of the PHOSP consortiumEnya Daynes, Molly Baldwin, Neil J Greening, et al.
The European Respiratory Journal|February 29, 2024
Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycosesRitesh Agarwal, Inderpaul Singh Sehgal, Valliappan Muthu, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Lower Airway Dysbiosis in NTM+ Bronchiectasis is Associated with NET-Predominant Severe PhenotypesShivani Singh, Fares Darawshy, Kirby Erlandson, et al.
International Journal of Cardiology|August 10, 2024
Diagnostic utility of electrocardiogram for screening of cardiac injury on cardiac magnetic resonance in post-hospitalised COVID-19 patients: a prospective multicenter studyAzlan Helmy Abd Samat, Mark P Cassar, Abid M Akhtar, et al.
Pageof 50

Showing results (471-480 of 494) with videos related to

Sort By:
Pageof 50
The Lancet. Respiratory Medicine|April 27, 2026
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort studyAmelia Shoemark, Emma D Johnson, Morven Shuttleworth, et al.
Eclinicalmedicine|March 20, 2023
Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort studyHamish J C McAuley, Rachael A Evans, Charlotte E Bolton, et al.
Thorax|March 23, 2025
Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)Jennifer Pollock, Eva Polverino, Raja Dhar, et al.
The European Respiratory Journal|April 12, 2024
Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)Stefano Aliberti, Felix C Ringshausen, Raja Dhar, et al.
Ebiomedicine|December 21, 2022
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccinationFelicity Liew, Shubha Talwar, Andy Cross, et al.
The Lancet. Respiratory Medicine|August 30, 2025
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational studyOriol Sibila, Jamie Stobo, Lidia Perea, et al.
Trials|January 26, 2023
The effect of COVID rehabilitation for ongoing symptoms Post HOSPitalisation with COVID-19 (PHOSP-R): protocol for a randomised parallel group controlled trial on behalf of the PHOSP consortiumEnya Daynes, Molly Baldwin, Neil J Greening, et al.
The European Respiratory Journal|February 29, 2024
Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycosesRitesh Agarwal, Inderpaul Singh Sehgal, Valliappan Muthu, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Lower Airway Dysbiosis in NTM+ Bronchiectasis is Associated with NET-Predominant Severe PhenotypesShivani Singh, Fares Darawshy, Kirby Erlandson, et al.
International Journal of Cardiology|August 10, 2024
Diagnostic utility of electrocardiogram for screening of cardiac injury on cardiac magnetic resonance in post-hospitalised COVID-19 patients: a prospective multicenter studyAzlan Helmy Abd Samat, Mark P Cassar, Abid M Akhtar, et al.
Pageof 50